Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2014

Li Jing, Kim Seongho, Sha Xianyi, Wiegand Richard, Wu Jianmei, LoRusso Patricia

Abstract excerpt

PURPOSE: Veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, undergoes renal excretion and liver metabolism. This study quantitatively assessed the interactions of veliparib with metabolizing enzyme (CYP2D6) and transporter (OCT2) in disease settings (renal impairment). EXPERIMENTAL DESIGN: Veliparib in vitro metabolism was examined in human liver microsomes and recombinant enzymes carrying wild-type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Clinical Trials, Phase I as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Organic Cation Transport Proteins

Share to Organic Cation Transporter 2

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Renal Insufficiency

Share to Tissue Distribution

Source

Open in PubMed Open full text

Identifiers

PMID: 24947923
DOI: 10.1158/1078-0432.CCR-14-0791
PMCID: PMC4151156

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.PMID 24947923Read ↗

Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.Semantic proximity Read ↗

Human Mass Balance and Metabolite Profiling of [14 C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer.Semantic proximity Read ↗

Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib.Semantic proximity Read ↗

A PBPK Digital Twin of Rapamycin for Predicting Dose–Exposure Relationships, Organ Impairment Effects, and Drug–Drug InteractionsSemantic proximity Read ↗

Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.Semantic proximity Read ↗

Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical ImplicationsSemantic proximity Read ↗

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Semantic proximity Read ↗

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.Semantic proximity Read ↗

Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.Semantic proximity Read ↗

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.Semantic proximity Read ↗

Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.